Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity
Authors:
- François MoisanFMFrançois Moisan
- Céline AuzanneauCACéline Auzanneau
- Nicolas RicardNRNicolas Ricard
- Philippe PourquierPhilippe Pourquier
- Jacques RobertJRJacques Robert
Open Access
- 15 February 2012
- journal article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 33 (5) , 962-968
Abstract
ERCC2 [Xeroderma pigmentosum (XP) group D] belongs to the nucleotide excision repair pathway. It is also part of the TFIIH transcription complex and is required for the association of the cyclin-dependent kinase (CDK)-activating kinase (CAK) subcomplex with TFIIH. Using the NCI-60 panel of human tumor cell lines, we had shown that the ERCC2 gene variant Gln751 was significantly associated to increased taxanes sensitivity and decreased ERCC2 gene expression. Since TFIIH is involved in both DNA repair and cell cycle progression, we hypothesized that quantitative or qualitative ERCC2 alterations might cause CAK liberation, allowing its activation of the G2/M transition. Enhancing mitosis entry would lead to hypersensitivity to spindle poisons, explaining the effect of ERCC2 polymorphisms on taxane sensitivity. Starting from ERCC2-deficient XP6BE, we generated several isogenic clones differing only by the Lys751Gln variation. Wild-type and variant ERCC2-expressing clones recovered ultraviolet radiation and cisplatin resistance but presented similar sensitivity to paclitaxel, demonstrating that the amino acid change was not involved in paclitaxel differential sensitivity in the NCI-60 panel. Using small interfering RNA approach, we knocked down ERCC2 expression and observed a block in the G2/M phase, with a consistent increase in paclitaxel sensitivity and no change in cisplatin sensitivity. We observed in addition an increase in CDK1 activity, as evaluated by histone H1 phosphorylation. We evaluated messenger RNA (mRNA) half-life in the isogenic lines and observed a more rapid degradation in cells bearing the variant construct. We concluded that the increased paclitaxel sensitivity of ERCC2 variant cell lines is a consequence of lower gene expression, likely due to decreased stability of the variant ERCC2 mRNA.Keywords
This publication has 19 references indexed in Scilit:
- Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapyJournal of Translational Medicine, 2011
- On the traces of XPD: cell cycle matters - untangling the genotype-phenotype relationship of XPD mutationsCell Division, 2010
- Drosophila Xpd Regulates Cdk7 Localization, Mitotic Kinase Activity, Spindle Dynamics, and Chromosome SegregationPLOS Genetics, 2010
- Topoisomerase II alpha as a marker predicting anthracyclines’ activity in early breast cancer patients: Ready for the primetime?European Journal of Cancer, 2008
- Common XPD (ERCC2) polymorphisms have no measurable effect on nucleotide excision repair and basal transcriptionDNA Repair, 2007
- Targeting the function of the HER2 oncogene in human cancer therapeuticsOncogene, 2007
- XPG Stabilizes TFIIH, Allowing Transactivation of Nuclear Receptors: Implications for Cockayne Syndrome in XP-G/CS PatientsMolecular Cell, 2007
- BRCA1 Downregulation Leads to Premature Inactivation of Spindle Checkpoint and Confers Paclitaxel ResistanceCell Cycle, 2006
- Microtubule Associated Protein (MAP)-Tau: A Novel Mediator of Paclitaxel Sensitivity In Vitro and In VivoCell Cycle, 2005
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005